The fact that diabetes impairs incretin function by attenuating GLP-1 and GIP responses (32) also likely contributed further to heterogeneity between studies, where some of which enrolled participants at early stages of diabetes, while others included those who were further along in the course of their disease. This evidence concerns the gene GCG and diabetes mellitus.